Ginkgo Bioworks Holdings, Inc. ( (DNA) ) has released its Q2 earnings. Here is a breakdown of the information Ginkgo Bioworks Holdings, Inc. presented to its investors.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Ginkgo Bioworks Holdings, Inc. is a company that specializes in cell programming and biosecurity, providing tools for engineering biology and offering services across therapeutics, diagnostics, and manufacturing. In its latest earnings report for the second quarter of 2025, Ginkgo Bioworks announced a total revenue of $50 million, a slight decrease from the previous year. The company reported an 8% increase in cell engineering revenue, driven by demand from biopharma and government sectors, while biosecurity revenue saw a decline. Despite a net loss of $60 million, the company improved its adjusted EBITDA to a loss of $28 million, a significant improvement from the previous year, due to reduced operating expenses. Ginkgo Bioworks highlighted its strategic advancements, including the launch of new services and products, and the achievement of a $250 million cost-saving target ahead of schedule. The company continues to focus on expanding its automation and data capabilities, securing major contracts, and enhancing its service offerings. Looking ahead, Ginkgo Bioworks maintains its revenue outlook for 2025 and aims to reach adjusted EBITDA breakeven by the end of 2026, reflecting confidence in its strategic direction and financial discipline.